Oral administration of 400 to 600 mcg of misoprostol is considered optimal for the prevention of PPH, and sublingual administration of 800 mcg of misoprostol is the route with the most evidence supporting its safety and efficacy for the treatment of PPH.[27,28] A limited number of studies have also demonstrated the effectiveness of intrauterine misoprostol in controlling PPH.[15,29] Another important purpose of our study was to compare the effects of different routes of administration: rectal and intrauterine (cornual) misoprostol combined with oxytocin. This evidence concerns the gene OXT and pulmonary arterial hypertension.